TD Cowen Maintains Buy on Aurinia Pharmaceuticals, Raises Price Target to $18
Benzinga Newsdesk 1 week ago
Analyst RatingsNewsPrice Target
TD Cowen analyst Stacy Ku maintains Aurinia Pharmaceuticals (NASDAQ:AUPH) with a Buy and raises the price target from $17 to $18.
TD Cowen analyst Stacy Ku maintains Aurinia Pharmaceuticals (NASDAQ:AUPH) with a Buy and raises the price target from $17 to $18.